G20: what did the leaders decide?
The G20 summit took place in Bali, Indonesia, on November 2022…
Moderna: is it still the leader in COVID-19 fight?
Information is not investment advice
While biotech companies are struggling to find the vaccine, investors make bets who’ll win this race.
Moderna has performed really well and skyrocketed close to 250% higher this year so far. If you had invested in it at the right time, you would have doubled or, in the best case, even tripled your account. Does it still have the potential to the upside? Opinions are divided.
On the one hand, Moderna revealed positive phase-1 results for a COVID-19 vaccine on May 18, what made it one of the most promising candidates in this race. The stock price reached its peak at $86 that day.
On the other hand, vaccine experts raised doubts about the potential effectiveness of the Moderna’s vaccine as the company revealed too little information. That pushed the stock price down to $70. Moreover, so many competitors have appeared, more than 100 already. The main competitor is Pfizer as it uses the same technology as Moderna.
Now everybody’s waiting for the phase-2 results. Follow the news as it can cause price movements. These days the price trades near $70. The retracement line is 73.5. Support levels are 62 and 48.
Consider buying these stocks
Inovio
INO stock has outperformed its competitors in 2020, posting gains over 390%. This is a very reliable company with a long history. It’s famous for its effective treatment to clinic for Ebola in 15 months, nine months for MERS and, six and a half months for Zika. It will release its first tests in June.
Gilead
This biotech company created the first coronavirus treatment that was approved by the government. You’ve probably heard of remdesivir. Clinical trials showed it reduced the recovery time required for some patients. Now the company just donates its medicine to hospitals in a huge amount. The question now is what the price will be when the company starts selling it. Piper Sandler analysts anticipate it may bring up to $2 billion in revenue in 2020. So, this company has a really great potential.
Investors from all over the world focus on biotech stocks now as it’s the great chance to make profit without many efforts. It appears not so often. Don’t miss it!
Similar
The End of Era: What Might the UK Face Next?
The deafening news shocked the whole world yesterday: the British Queen Elizabeth II died peacefully at the age of 96…
Why didn't oil prices calm despite OPEC+ attempts?
After months of pressure from the White House, Saudi Arabia relented and agreed with other OPEC+ members to increase production.
Popular
European Currencies Ahead of the Banks' Statements
On Thursday, the 2nd of February, the Bank of England will publish its report concerning interest rates and inflation data for the Eurozone. Professionals and investors anticipate that Andrew Bailey’s lead team of policy makers will likely raise interest rates to 4%; the highest in over a decade, for the tenth time in a row.
Will the FOMC Surprise the Markets?
The first FOMC meeting comes after a buildup of anticipation from traders and investors alike, as the markets await what posture the Fed will take regarding the interest rates; would there be a hike or a cut in interest rates? Recall that the Federal Open Market Committee had previously ended the year 2022 with a 50bps hike, and an indication from Powell, the committee chairman, that the Fed could consider raising interest rates by 75bps in the course of the year 2023.
What awaits the Oil Market in February?
Western countries are trying to find other options for oil and gas supplies after a 10th package of sanctions, which will put more pressure on Russian oil and decrease global oil supply. Italy, for example, is in talks with Libya.
Choose your payment system
